A Multifactorial Likelihood Model for MMR Gene Variant Classification Incorporating Probabilities Based on Sequence Bioinformatics and Tumor Characteristics: A Report from the Colon Cancer Family Registry

Mismatch repair (MMR) gene sequence variants of uncertain clinical significance are often identified in suspected Lynch syndrome families, and this constitutes a challenge for both researchers and clinicians. Multifactorial likelihood model approaches provide a quantitative measure of MMR variant pathogenicity, but first require input of likelihood ratios (LRs) for different MMR variation‐associated characteristics from appropriate, well‐characterized reference datasets. Microsatellite instability (MSI) and somatic BRAF tumor data for unselected colorectal cancer probands of known pathogenic variant status were used to derive LRs for tumor characteristics using the Colon Cancer Family Registry (CFR) resource. These tumor LRs were combined with variant segregation within families, and estimates of prior probability of pathogenicity based on sequence conservation and position, to analyze 44 unclassified variants identified initially in Australasian Colon CFR families. In addition, in vitro splicing analyses were conducted on the subset of variants based on bioinformatic splicing predictions. The LR in favor of pathogenicity was estimated to be ∼12‐fold for a colorectal tumor with a BRAF mutation‐negative MSI‐H phenotype. For 31 of the 44 variants, the posterior probabilities of pathogenicity were such that altered clinical management would be indicated. Our findings provide a working multifactorial likelihood model for classification that carefully considers mode of ascertainment for gene testing.

[1]  Predrag Radivojac,et al.  Calibration of Multiple In Silico Tools for Predicting Pathogenicity of Mismatch Repair Gene Missense Substitutions , 2013, Human mutation.

[2]  F. Couch,et al.  The germline MLH1 K618A variant and susceptibility to Lynch syndrome-associated tumors. , 2012, Journal of Molecular Diagnostics.

[3]  A. Spurdle,et al.  Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification , 2012, Journal of Medical Genetics.

[4]  F. Couch,et al.  Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary , 2011, Human mutation.

[5]  J. Fléjou,et al.  Microsatellite instability in colorectal cancer: from molecular oncogenic mechanisms to clinical implications , 2011, Cellular Oncology.

[6]  A. Viel,et al.  Integrated analysis of unclassified variants in mismatch repair genes , 2011, Genetics in Medicine.

[7]  Á. Carracedo,et al.  Evidence for classification of c.1852_1853AA>GC in MLH1 as a neutral variant for Lynch syndrome , 2011, BMC Medical Genetics.

[8]  F. Hogervorst,et al.  A novel pathogenic MLH1 missense mutation, c.112A > C, p.Asn38His, in six families with Lynch syndrome , 2010, Hereditary cancer in clinical practice.

[9]  Aung Ko Win,et al.  Risk Factors for Colorectal Cancer in Patients with Multiple Serrated Polyps: A Cross-Sectional Case Series from Genetics Clinics , 2010, PloS one.

[10]  A. Spurdle Clinical relevance of rare germline sequence variants in cancer genes: evolution and application of classification models. , 2010, Current opinion in genetics & development.

[11]  E. Stoffel,et al.  Effect of smoking on urothelial cancer risk in individuals with Lynch syndrome , 2010, Hereditary Cancer in Clinical Practice.

[12]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[13]  Finlay Macrae,et al.  Risks of Lynch syndrome cancers for MSH6 mutation carriers. , 2010, Journal of the National Cancer Institute.

[14]  P. Hutter,et al.  Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation , 2010, Familial Cancer.

[15]  H T Lynch,et al.  Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications , 2009, Clinical genetics.

[16]  John L Hopper,et al.  Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics , 2009, Human mutation.

[17]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.

[18]  M. Woods,et al.  Analysis of families with Lynch syndrome complicated by advanced serrated neoplasia: the importance of pathology review and pedigree analysis , 2009, Familial Cancer.

[19]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[20]  F. Couch,et al.  Prediction and assessment of splicing alterations: implications for clinical testing , 2008, Human mutation.

[21]  S. Tavtigian,et al.  In silico analysis of missense substitutions using sequence‐alignment based methods , 2008, Human mutation.

[22]  F. Couch,et al.  Assessment of functional effects of unclassified genetic variants , 2008, Human mutation.

[23]  N. de Wind,et al.  Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance , 2008, Human mutation.

[24]  Douglas F Easton,et al.  Genetic evidence and integration of various data sources for classifying uncertain variants into a single model , 2008, Human mutation.

[25]  J. Lindebjerg,et al.  Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency , 2008, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[26]  H. Campbell,et al.  Classification of ambiguous mutations in DNA mismatch repair genes identified in a population‐based study of colorectal cancer , 2008, Human mutation.

[27]  B. Bellosillo,et al.  A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  B. Bapat,et al.  The MLH1 variants p.Arg265Cys and p.Lys618Ala affect protein stability while p.Leu749Gln affects heterodimer formation , 2008, Human mutation.

[29]  O. Csuka,et al.  Two germline alterations in mismatch repair genes found in a HNPCC patient with poor family history , 2006, Pathology & Oncology Research.

[30]  Fergus J Couch,et al.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. , 2007, American journal of human genetics.

[31]  John D Potter,et al.  Colon Cancer Family Registry: An International Resource for Studies of the Genetic Epidemiology of Colon Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[32]  Michael O Woods,et al.  A new variant database for mismatch repair genes associated with Lynch syndrome , 2007, Human mutation.

[33]  M. Trivett,et al.  Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer , 2007, Familial Cancer.

[34]  K. Kinzler,et al.  Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. , 2007, Journal of the National Cancer Institute.

[35]  P. Radice,et al.  A human cell-based assay to evaluate the effects of alterations in the MLH1 mismatch repair gene. , 2006, Cancer research.

[36]  A. Viel,et al.  Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features , 2006, European Journal of Human Genetics.

[37]  M. Genuardi,et al.  The use of microsatellite instability, immunohistochemistry and other variables in determining the clinical significance of MLH1 and MSH2 unclassified variants in Lynch syndrome. , 2006, Cancer biomarkers : section A of Disease markers.

[38]  M. Kloor,et al.  Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer , 2006, International journal of cancer.

[39]  P. Propping,et al.  Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining , 2005, The Journal of pathology.

[40]  D. Baralle,et al.  Splicing in action: assessing disease causing sequence changes , 2005, Journal of Medical Genetics.

[41]  J. Trojan,et al.  BRAF mutations in colorectal carcinoma suggest two entities of microsatellite‐unstable tumors , 2005, Cancer.

[42]  A. Sidow,et al.  Physicochemical constraint violation by missense substitutions mediates impairment of protein function and disease severity. , 2005, Genome research.

[43]  Hiroyuki Yamamoto,et al.  BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes , 2005, Oncogene.

[44]  H C van Houwelingen,et al.  Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment , 2005, Journal of Medical Genetics.

[45]  J. Hopper,et al.  Evidence for BRAF mutation and variable levels of microsatellite instability in a syndrome of familial colorectal cancer. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[46]  J. Perkel,et al.  The yeast two-hybrid assay , 2005 .

[47]  Prathap Bandipalliam Syndrome of Early Onset Colon Cancers, Hematologic Malignancies & Features of Neurofibromatosis in HNPCC Families with Homozygous Mismatch Repair Gene Mutations , 2005, Familial Cancer.

[48]  P. Peltomäki,et al.  Mutations Associated with HNPCC Predisposition — Update of ICG-HNPCC/INSiGHT Mutation Database , 2004, Disease markers.

[49]  F. Couch,et al.  Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. , 2004, American journal of human genetics.

[50]  L. Aaltonen,et al.  BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing , 2004, Journal of Medical Genetics.

[51]  R. Weksberg,et al.  Gastrointestinal cancers and neurofibromatosis type 1 features in children with a germline homozygous MLH1 mutation. , 2004, Gastroenterology.

[52]  G. Deng,et al.  BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer , 2004, Clinical Cancer Research.

[53]  B. Leggett,et al.  Promoter Hypermethylation Frequency and BRAF Mutations Distinguish Hereditary Non-Polyposis Colon Cancer from Sporadic MSI-H Colon Cancer , 2004, Familial Cancer.

[54]  D. Schaid,et al.  BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. , 2003, Cancer research.

[55]  Douglas F Easton,et al.  A full-likelihood method for the evaluation of causality of sequence variants from family data. , 2003, American journal of human genetics.

[56]  Hideyuki Suzuki,et al.  A yeast two-hybrid assay provides a simple way to evaluate the vast majority of hMLH1 germ-line mutations. , 2003, Cancer research.

[57]  Christopher B. Burge,et al.  Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals , 2003, RECOMB '03.

[58]  P. Gregersen,et al.  The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. , 2002, American journal of human genetics.

[59]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[60]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[61]  M. Benito,et al.  Prevalence of germline mutations of MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer families from Spain , 2002, International journal of cancer.

[62]  Daniel J Sargent,et al.  Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  H. Nagai,et al.  Extensive methylation of hMLH1 promoter region predominates in proximal colon cancer with microsatellite instability. , 2001, Gastroenterology.

[64]  D. Aust,et al.  Sixteen rare sequence variants of the hMLH1 and hMSH2 genes found in a cohort of 254 suspected HNPCC (hereditary non-polyposis colorectal cancer) patients: mutations or polymorphisms? , 2001, European journal of medical research.

[65]  V. Weinberg,et al.  Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. , 2001, Gastroenterology.

[66]  Anastassis Perrakis,et al.  The crystal structure of DNA mismatch repair protein MutS binding to a G·T mismatch , 2000, Nature.

[67]  Wei Yang,et al.  Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA , 2000, Nature.

[68]  L. Aaltonen,et al.  Population-based molecular detection of hereditary nonpolyposis colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  W. Foulkes,et al.  A missense mutation in both hMSH2 andAPC in an Ashkenazi Jewish HNPCC kindred: implications for clinical screening , 1999, Journal of medical genetics.

[70]  J. Saurin,et al.  Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer , 1999, Human Genetics.

[71]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[72]  R. Fishel,et al.  The Interaction of the Human MutL Homologues in Hereditary Nonpolyposis Colon Cancer* , 1999, The Journal of Biological Chemistry.

[73]  A. Viel,et al.  Lack of PMS2 gene-truncating mutations in patients with hereditary colorectal cancer. , 1998, International journal of oncology.

[74]  S N Thibodeau,et al.  Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. , 1998, Cancer research.

[75]  J. Herman,et al.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[76]  L. Aaltonen,et al.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.

[77]  A. Viel,et al.  MLH1 and MSH2 constitutinal mutations in colorectal cancer families not meeting the standard criteria for hereditary nonpolyposis colorectal cancer , 1998, International journal of cancer.

[78]  David Haussler,et al.  Improved splice site detection in Genie , 1997, RECOMB '97.

[79]  B. Sugden,et al.  Clonal transformation of adult human leukocytes by Epstein-Barr virus , 1977, Journal of virology.